SEC STATUS

​

Stramsen Biotech, Inc. has been a pioneering force in the biopharmaceutical industry since our inception in November 2020. Over the past three years, we've made significant strides in developing groundbreaking plant-based medicines, positioning ourselves at the forefront of innovation in patient care.

​

After careful consideration of numerous merger and reverse merger offers from publicly traded companies, we've made a strategic decision to chart our own course towards an Initial Public Offering (IPO). This bold move underscores our confidence in our long-term vision and our commitment to maintaining the stability and integrity of our revolutionary approach to medicine.

​

We're excited to announce our plans to file an S-1 prospectus with the U.S. Securities and Exchange Commission in early 2025, marking a significant milestone in our journey. As a precursor to this momentous event, we intend to file a Regulation A offering with the SEC in early October 2024, presenting a unique opportunity for investors to be part of our groundbreaking work.

​

Stramsen Biotech Inc. is poised to raise up to $75,000,000 through our Regulation A offering circular. We're leveraging a strategic combination of private fundraising options, including Regulation D, Regulation A, and Regulation Crowdfunding (CF). This multi-faceted approach allows us to tap into diverse investor pools, maximizing our potential for growth and innovation.

​

While our primary focus for capital raising will be via private markets, our upcoming IPO serves a crucial purpose: registering our investors' and shareholders' stocks. This approach ensures we can reward those who have believed in our vision from the start while opening doors for new investors to join our journey.

​

As we prepare for this exciting new chapter, Stramsen Biotech, Inc. is actively seeking partnership with premier investment banks to serve as underwriters for our IPO. We invite interested parties to contact us promptly to explore this exceptional opportunity to be part of a transformative force in biopharmaceuticals.

We're thrilled to announce that we've already taken significant steps towards our public offering. On May 20th, 2024, we filed Form Regulation D Rule 506(c) with the SEC,

 

As of June 2025, Stramsen Biotech Inc. boasts a robust equity capital structure designed to support its ambitious growth plans. The company has authorized 750 million shares, with approximately 229,041,217 shares currently outstanding. Based on the most recent valuation of $6.5 billion, our share price in the private market stands at approximately $28.38 per share. This valuation reflects the market's confidence in our innovative biotech solutions and potential for future growth.

​

Join us in our mission to revolutionize patient care through plant-based medicines. Invest in Stramsen Biotech, Inc. - where nature meets innovation, and transformation becomes reality.

​

Please click on the link below for more information,

​

EDGAR Search Results (sec.gov)

​

 

​